Welcome to our dedicated page for CELLECTAR BIOSC news (Ticker: CLRBZ), a resource for investors and traders seeking the latest updates and insights on CELLECTAR BIOSC stock.
The CLRBZ news page aggregates recent disclosures and media coverage related to Cellectar Biosciences, Inc., a late-stage clinical radiopharmaceutical and biotechnology company listed on NASDAQ under the symbol CLRB. Company communications describe Cellectar as focused on developing phospholipid-based targeted radiotherapeutics and radioconjugates for the treatment of cancer.
News items associated with CLRBZ and Cellectar typically cover updates on the company’s lead asset iopofosine I 131, an iodine-131 Phospholipid Drug Conjugate designed for hematologic and solid tumor cancers, as well as pipeline programs such as CLR 121125 (CLR 125), an iodine-125 Auger-emitting candidate for solid tumors, and CLR 121225 (CLR 225), an actinium-225 based candidate for pancreatic and other cancers. Coverage often includes clinical trial milestones, such as Phase 2b and Phase 1b study updates in Waldenstrom’s macroglobulinemia and pediatric high-grade glioma, and early-stage development plans in triple-negative breast cancer and pancreatic ductal adenocarcinoma.
Investors and observers can use this news feed to follow regulatory developments described by the company, including FDA designations like Breakthrough Therapy, Orphan Drug, Rare Pediatric Disease, and Fast Track, as well as EMA PRIME and orphan designations. Announcements may also highlight guidance from the European Medicines Agency’s Scientific Advice Working Party on potential Conditional Marketing Authorization pathways, along with information on isotope supply agreements and clinical research partnerships.
By reviewing the CLRBZ news page, readers can track how Cellectar characterizes progress across its PDC-based radiotherapeutic pipeline, including scientific presentations, preclinical data releases, financing transactions, and collaboration agreements that the company reports as supporting its oncology programs.
Cellectar Biosciences (NASDAQ:CLRB) has successfully closed its previously announced underwritten public offering, raising $6.9 million in gross proceeds. The offering consisted of 1,045,000 Class A Units priced at $5.00 each and 335,000 Class B Units at $4.99999 each, including the full exercise of the over-allotment option.
Each Class A Unit includes one common stock share and one common warrant, while Class B Units contain one pre-funded warrant and one common warrant. The Common Warrants have a $5.25 exercise price and a 5-year term. The company plans to use proceeds for general corporate purposes and to initiate a Phase 1b clinical study of CLR 121125 in triple-negative breast cancer.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on cancer drug development, has announced the pricing of an underwritten public offering to raise approximately $6 million in gross proceeds.
The offering consists of 865,000 Class A Units at $5.00 per unit (including one common stock share and one common warrant) and 335,000 Class B Units at $4.99999 per unit (including one pre-funded warrant and one common warrant). The common warrants will have an exercise price of $5.25 per share with a five-year term.
The company plans to use the proceeds for general corporate purposes, working capital, and to initiate a Phase 1b clinical study of CLR 121125 (CLR 125) in triple-negative breast cancer. Ladenburg Thalmann & Co. Inc. is serving as the sole bookrunning manager, with the offering expected to close around July 2, 2025.
Cellectar Biosciences (NASDAQ: CLRB) has entered into a multi-year supply agreement with Nusano for the provision of iodine-125 (I-125) and actinium-225 (Ac-225) isotopes. The partnership will support Cellectar's radiotherapeutic pipeline development, including CLR 125 for triple negative breast cancer and CLR 225 for pancreatic cancer.
The isotopes will be produced at Nusano's next-generation facility in Utah, ensuring uninterrupted access to these essential materials for both clinical development and future commercial needs. This strategic partnership addresses critical supply chain challenges in the production of rare medical radioisotopes at commercial scale.
Cellectar Biosciences (NASDAQ:CLRB) has submitted a protocol to the FDA for a Phase 1b dose-finding study of CLR 125, an Auger-emitting radiopharmaceutical for treating triple-negative breast cancer (TNBC). The study will evaluate three different dosing regimens across 15 patients per arm, totaling 45 patients.
The trial aims to determine the recommended Phase 2 dose, assess safety and tolerability, and evaluate initial response using RECIST criteria and progression-free survival. CLR 125 showed promising preclinical results, demonstrating good tolerability and robust tumor uptake in TNBC animal models. The drug leverages the company's PDC-targeted delivery platform to deliver iodine-125 directly to cancer cell nuclei and mitochondria.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has scheduled its first quarter 2025 financial results announcement and corporate update for May 13, 2025, at 8:30 AM ET. The company will host a conference call accessible via toll-free number 1-800-717-1738 (Conference ID: 53983) and webcast. A replay of the presentation will be made available in the Events section of the company's Investor Relations website.